Arctic Bioscience – Invitation to webcast – HeROPA read-out
With reference to stock exchange release regarding the results from the HeROPA clinical trial read-out.
Arctic Bioscience will host a webcast tomorrow Wednesday 16th of October 2024 at 12:00 CET, to present the results from the HeROPA read-out.
The webcast will be hosted by CEO Christer L. Valderhaug and Medical Director Runhild Gammelsæter.
Webcast details:
Date: Wednesday 16th of October 2024
Time: 12:00 CET
Format: Webcast
Language: English
The presentation can be accessed through the link below:
Link: https://channel.royalcast.com/landingpage/hegnarmedia/20241016_1/
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Mobile: +47 920 84 601
E-mail: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.